CG2001

CG2001 is an investigational **topical fixed-dose foam combination of minoxidil and finasteride** developed by Dayspring Pharma for **male androgenetic alopecia**. Minoxidil promotes hair-follicle activity and prolongs the anagen growth phase, while finasteride inhibits steroid 5-alpha-reductase to reduce local formation of dihydrotestosterone, a central driver of androgen-dependent follicular miniaturization. The program has completed Phase II testing in Chinese adult men, with reported formulations including 5% minoxidil combined with 0.075% or 0.1% finasteride.

Other names

minoxidil + finasteride foamminoxidil finasteride foam